{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:23:40Z","timestamp":1792844620135,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:00:00Z","timestamp":1491868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/bjc.2017.88","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T20:02:23Z","timestamp":1491940943000},"page":"1366-1373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Tyrosine kinase-targeting drugs-associated heart failure"],"prefix":"10.1038","volume":"116","author":[{"given":"N","family":"Gronich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Lavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Barnett-Griness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D R","family":"Abernethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rennert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,11]]},"reference":[{"key":"BFbjc201788_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O\u2019Shaughnessy J (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124\u20131130.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","volume":"14","author":"M Brave","year":"2008","unstructured":"Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14: 352\u2013359.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201788_CR3","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","volume":"9","author":"AC Braverman","year":"1991","unstructured":"Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT (1991) Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9: 1215\u20131223.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR4","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","volume":"31","author":"M Chavez-MacGregor","year":"2013","unstructured":"Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31: 4222\u20134228.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR5","doi-asserted-by":"publisher","first-page":"187ra69","DOI":"10.1126\/scitranslmed.3005066","volume":"5","author":"V Chintalgattu","year":"2013","unstructured":"Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K Jr, Pati S, Bankson JA, Pasqualini R, Arap W, Bryan NS, Taegtmeyer H, Langley RR, Yao H, Kupferman ME, Entman ML, Dickinson ME, Khakoo AY (2013) Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci Transl Med 5: 187ra69.","journal-title":"Sci Transl Med"},{"key":"BFbjc201788_CR6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370: 2011\u20132019.","journal-title":"Lancet"},{"key":"BFbjc201788_CR7","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/imj.13201","volume":"46","author":"RA Clark","year":"2016","unstructured":"Clark RA, Berry NM, Chowdhury MH, McCarthy AL, Ullah S, Versace VL, Atherton JJ, Koczwara B, Roder D (2016) Heart failure following cancer treatment characteristics, survival and mortality of a linked health data analysis. Intern Med J 46: 1297\u20131306.","journal-title":"Intern Med J"},{"key":"BFbjc201788_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459\u2013465.","journal-title":"Nat Med"},{"key":"BFbjc201788_CR9","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase 3 study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25: 1346\u20131355.","journal-title":"Ann Oncol"},{"key":"BFbjc201788_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","volume":"13","author":"T Eschenhagen","year":"2011","unstructured":"Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13: 1\u201310.","journal-title":"Eur J Heart Fail"},{"key":"BFbjc201788_CR11","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312\u20133318.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR12","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","volume":"50","author":"MS Ewer","year":"2014","unstructured":"Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ (2014) Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer 50: 2162\u20132170.","journal-title":"Eur J Cancer"},{"key":"BFbjc201788_CR13","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM (2005a) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23: 2900\u20132902.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR14","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ (2005b) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820\u20137826.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR15","doi-asserted-by":"publisher","first-page":"i4351","DOI":"10.1136\/bmj.i4351","volume":"354","author":"MM Fidler","year":"2016","unstructured":"Fidler MM, Reulen RC, Winter DL, Kelly J, Jenkinson HC, Skinner R, Frobisher C, Hawkins MM British Childhood Cancer Survivor Study Steering Group (2016) Long term cause specific mortality among 34\u2009489 five year survivors of childhood cancer in Great Britain: population based cohort study. BMJ 354: i4351.","journal-title":"BMJ"},{"key":"BFbjc201788_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","volume":"374","author":"KB Filion","year":"2016","unstructured":"Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P CNODES Investigators (2016) A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 374: 1145\u20131154.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM (1986) Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68: 1114\u20131118.","journal-title":"Blood"},{"key":"BFbjc201788_CR18","doi-asserted-by":"publisher","first-page":"djv301","DOI":"10.1093\/jnci\/djv301","volume":"108","author":"HA Goldhar","year":"2015","unstructured":"Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK (2015) The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study. J Natl Cancer Inst 108: djv301.","journal-title":"J Natl Cancer Inst"},{"key":"BFbjc201788_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","volume":"141","author":"JS Gottdiener","year":"1981","unstructured":"Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J (1981) Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141: 758\u2013763.","journal-title":"Arch Intern Med"},{"key":"BFbjc201788_CR20","doi-asserted-by":"publisher","first-page":"E1319","DOI":"10.1503\/cmaj.110463","volume":"183","author":"N Gronich","year":"2011","unstructured":"Gronich N, Lavi I, Rennert G (2011) Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 183: E1319\u2013E1325.","journal-title":"CMAJ"},{"key":"BFbjc201788_CR21","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1124\/mol.108.050104","volume":"74","author":"BB Hasinoff","year":"2008","unstructured":"Hasinoff BB, Patel D, O\u2019Hara KA (2008) Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 74: 1722\u20131728.","journal-title":"Mol Pharmacol"},{"key":"BFbjc201788_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/sj.bjc.6604909","volume":"100","author":"AL Jones","year":"2009","unstructured":"Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100: 684\u2013692.","journal-title":"Br J Cancer"},{"key":"BFbjc201788_CR23","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O\u2019Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538\u20135546.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR24","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908\u2013916.","journal-title":"Nat Med"},{"key":"BFbjc201788_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1752-8062.2008.00090.x","volume":"2","author":"R Kerkela","year":"2009","unstructured":"Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T (2009) Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2: 15\u201325.","journal-title":"Clin Transl Sci"},{"key":"BFbjc201788_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ejheart.2005.04.001","volume":"7","author":"AU Khand","year":"2005","unstructured":"Khand AU, Shaw M, Gemmel I, Cleland JG (2005) Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure. Eur J Heart Fail 7: 792\u2013797.","journal-title":"Eur J Heart Fail"},{"key":"BFbjc201788_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3324\/haematol.2011.058776","volume":"97","author":"TD Kim","year":"2012","unstructured":"Kim TD, le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, Giles FJ, D\u00f6rken B, Haverkamp W, K\u00f6hncke C (2012) Clinical cardiac safety profile of nilotinib. Haematologica 97: 883\u2013889.","journal-title":"Haematologica"},{"key":"BFbjc201788_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172\u2013187.","journal-title":"N Engl J Med"},{"issue":"7","key":"BFbjc201788_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ejheart.2008.05.006","volume":"10","author":"T K\u00fcmler","year":"2008","unstructured":"K\u00fcmler T, Gislason GH, Kirk V, Bay M, Nielsen OW, K\u00f8ber L, Torp-Pedersen C (2008) Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 10 (7): 658\u2013660.","journal-title":"Eur J Heart Fail"},{"key":"BFbjc201788_CR30","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFbjc201788_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00005650-200502000-00012","volume":"43","author":"DS Lee","year":"2005","unstructured":"Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV (2005) Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 43: 182\u2013188.","journal-title":"Med Care"},{"key":"BFbjc201788_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/08977194.2015.1010643","volume":"33","author":"A Li","year":"2015","unstructured":"Li A, Huang X, Song Y, Chen X, Sun J, Xu H, Wang Z (2015) Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis. Growth Factors 33: 113\u2013127.","journal-title":"Growth Factors"},{"key":"BFbjc201788_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/FJC.0000000000000163","volume":"65","author":"IT Mak","year":"2015","unstructured":"Mak IT, Kramer JH, Chmielinska JJ, Spurney CF, Weglicki WB (2015) EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade. J Cardiovasc Pharmacol 65: 54\u201361.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFbjc201788_CR34","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C Breast Cancer International Research Group 001 Investigators (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302\u20132313.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR35","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Ant\u00f3n A, Lluch A, Kennedy J, O\u2019Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265\u20134274.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR36","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1056\/NEJMoa0807154","volume":"360","author":"I Matok","year":"2009","unstructured":"Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A (2009) The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 360: 2528\u20132535.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR37","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2146\/ajhp100637","volume":"68","author":"CB Maxwell","year":"2011","unstructured":"Maxwell CB, Jenkins AT (2011) Drug-induced heart failure. Am J Health Syst Pharm 68: 1791\u20131804.","journal-title":"Am J Health Syst Pharm"},{"key":"BFbjc201788_CR38","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1158\/1078-0432.CCR-10-1969","volume":"17","author":"HL McArthur","year":"2011","unstructured":"McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D\u2019Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN (2011) A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 17: 3398\u20134407.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201788_CR39","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","volume":"375","author":"JJ Moslehi","year":"2016","unstructured":"Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 375: 1457\u20131467.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115\u2013124.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR42","doi-asserted-by":"publisher","first-page":"8880","DOI":"10.1073\/pnas.122249299","volume":"99","author":"C Ozcelik","year":"2002","unstructured":"Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, H\u00fcbner N, Chien KR, Birchmeier C, Garratt AN (2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA 99: 8880\u20138885.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc201788_CR43","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page 2nd","year":"2016","unstructured":"Page RL 2nd, O\u2019Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research (2016) Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 134: e32\u2013e69.","journal-title":"Circulation"},{"key":"BFbjc201788_CR44","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26: 1231\u20131238.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.7326\/0003-4819-118-1-199301010-00006","volume":"118","author":"ZM Quezado","year":"1993","unstructured":"Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP (1993) High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118: 31\u201336.","journal-title":"Ann Intern Med"},{"key":"BFbjc201788_CR46","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/MPH.0b013e3181f46e65","volume":"33","author":"V Radhakrishnan","year":"2011","unstructured":"Radhakrishnan V, Bakhshi S (2011) 5-Fluorouracil-induced acute dilated cardiomyopathy in a pediatric patient. J Pediatr Hematol Oncol 33: 323.","journal-title":"J Pediatr Hematol Oncol"},{"key":"BFbjc201788_CR47","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1136\/oem.2004.014472","volume":"61","author":"DB Richardson","year":"2004","unstructured":"Richardson DB . An incidence density sampling program for nested case-control analyses (2004) Occup Environ Med 61: e59.","journal-title":"Occup Environ Med"},{"key":"BFbjc201788_CR48","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/9781119959946.ch47","volume-title":"Pharmacoepidemiology","author":"S Schneeweiss","year":"2012","unstructured":"Schneeweiss S, Suissa S (2012) Advanced approaches to controlling confounding in pharmacoepidemiologic studies. In PharmacoepidemiologyBL Strom, SE Kimmel, S Hennessy, (eds), pp 868\u2013891. Wiley-Blackwell: Chichester, UK."},{"key":"BFbjc201788_CR49","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215\u20131221.","journal-title":"J Clin Oncol"},{"key":"BFbjc201788_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220\u2013241.","journal-title":"CA Cancer J Clin"},{"key":"BFbjc201788_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1445-5994.2009.02144.x","volume":"40","author":"T Stewart","year":"2010","unstructured":"Stewart T, Pavlakis N, Ward M (2010) Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J 40: 303\u2013307.","journal-title":"Intern Med J"},{"key":"BFbjc201788_CR52","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116\u20131127.","journal-title":"N Engl J Med"},{"key":"BFbjc201788_CR53","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53: 2231\u20132247.","journal-title":"J Am Coll Cardiol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201788","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:41:52Z","timestamp":1684417312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,11]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFbjc201788"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.88","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,11]]},"assertion":[{"value":"30 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}